

DAFTAR PUSTAKA

1. World Health Organization (WHO). Cardiovascular Diseases (CVDs) Fact Sheet. 2023.
2. Xue P, Lin L, Li P, Cheng S, Chen D, Fan M, et al. Global, regional, and national epidemiology of ischemic heart disease among individuals aged 55 and above from 1990 to 2021: a cross-sectional study. *BMC Public Health*. 2025;25.
3. Conrad N, Molenberghs G, Verbeke G, Zaccardi F, Lawson C, Friday JM, et al. Trends in cardiovascular disease incidence among 22 million people in the UK over 20 years: population based study. *BMJ*. 2024;
4. Bozkurt B, Ahmad T, Alexander KM, Baker WL, Bosak K, Breathett K, et al. Heart Failure Epidemiology and Outcomes Statistics: A Report of the Heart Failure Society of America. *J Card Fail*. 2023;29:1412–51.
5. Di Cesare M, McGhie DV, Perel P, Mwangi J, Taylor S, Pervan B, et al. The Heart of the World. *Glob Heart*. 2024;19.
6. RISKEDAS. Hasil Utama RISKEDAS. Hasil Utama RISKEDAS. 2018;1–57.
7. Saleh Nur Fajrurrachman, Pratiwi Dian, Masrik Nur Upik En. Karakteristik Penderita PJK di RSUD Dr. H. Chasan Boesoirie Ternate. 2022;4.
8. Komaroff AL. The microbiome and risk for atherosclerosis. Vol. 319, *JAMA - Journal of the American Medical Association*. American Medical Association; 2018. p. 2381–2.
9. Lehtiniemi J, Karhunen PJ, Goebeler S, Nikkari S, Nikkari ST. Identification of different bacterial DNAs in human coronary arteries. Vol. 35, *European Journal of Clinical Investigation*. 2005.
10. Brandsma E, Kloosterhuis NJ, Koster M, Dekker DC, Gijbels MJJ, Van Der Velden S, et al. A Proinflammatory Gut Microbiota Increases Systemic Inflammation and Accelerates Atherosclerosis. *Circ Res*. 2019;124:94–100.
11. Amiri P, Hosseini SA, Ghaffari S, Tutunchi H, Ghaffari S, Mosharkesh E, et al. Role of Butyrate, a Gut Microbiota Derived Metabolite, in Cardiovascular Diseases: A comprehensive narrative review. Vol. 12, *Frontiers in Pharmacology*. Frontiers Media S.A.; 2022.
12. Budaj A, Buechel RR, Alfonso Chiariello G, Grete Semb A, Senior R, Van Craenenbroeck EM, et al. Milan Milojevic 1 (Serbia). Torsten Doenst [Internet]. 1. Available from: <https://doi.org/10.1093/eurheartj/ehae177>
13. Vrints C, Andreotti F, Koskinas KC, Rossello X, Adamo M, Ainslie J, et al. 2024 ESC Guidelines for the management of chronic coronary syndromes. *Eur Heart J* [Internet]. 2024;45:3415–537. Available from: <https://academic.oup.com/eurheartj/article/45/36/3415/7743115>
14. Młynarska E, Czarnik W, Fularski P, Hajdys J, Majchrowicz G, Stabrawa M, et al. From Atherosclerotic Plaque to Myocardial Infarction—The Leading Cause of Coronary Artery Occlusion. Vol. 25, *International Journal of Molecular Sciences*. Multidisciplinary Digital Publishing Institute (MDPI); 2024.
15. Trøseid M, Andersen GØ, Broch K, Hov JR. The gut microbiome in coronary artery disease and heart failure: Current knowledge and future directions. Vol. 52, *EBioMedicine*. Elsevier B.V.; 2020.
16. Al Samarraie A, Pichette M, Rousseau G. Role of the Gut Microbiome in the Development of Atherosclerotic Cardiovascular Disease. Vol. 24, *International*

Journal of Molecular Sciences. Multidisciplinary Digital Publishing Institute (MDPI); 2023.

17. Singh V, Lee GD, Son HW, Koh H, Kim ES, Unno T, et al. Butyrate producers, “The Sentinel of Gut”: Their intestinal significance with and beyond butyrate, and prospective use as microbial therapeutics. Vol. 13, *Frontiers in Microbiology*. Frontiers Media S.A.; 2023.
18. Chen X, Zhang H, Ren S, Ding Y, Remex NS, Bhuiyan MS, et al. Gut microbiota and microbiota-derived metabolites in cardiovascular diseases. Vol. 136, *Chinese Medical Journal*. Lippincott Williams and Wilkins; 2023. p. 2269–84.
19. Chen W, Zhang S, Wu J, Ye T, Wang S, Wang P, et al. Butyrate-producing bacteria and the gut-heart axis in atherosclerosis. Vol. 507, *Clinica Chimica Acta*. Elsevier B.V.; 2020. p. 236–41.
20. Liu H, Wang J, He T, Becker S, Zhang G, Li D, et al. Butyrate: A double-edged sword for health? Vol. 9, *Advances in Nutrition*. Oxford University Press; 2018. p. 21–9.
21. Mayorga-Ramos A, Barba-Ostria C, Simancas-Racines D, Guamán LP. Protective role of butyrate in obesity and diabetes: New insights. Vol. 9, *Frontiers in Nutrition*. Frontiers Media S.A.; 2022.
22. Ohira H, Tsutsui W, Fujioka Y. Are short chain fatty acids in gut microbiota defensive players for inflammation and atherosclerosis? Vol. 24, *Journal of Atherosclerosis and Thrombosis*. Japan Atherosclerosis Society; 2017. p. 660–72.
23. Mayorga-Ramos A, Barba-Ostria C, Simancas-Racines D, Guamán LP. Protective role of butyrate in obesity and diabetes: New insights. Vol. 9, *Frontiers in Nutrition*. Frontiers Media S.A.; 2022.
24. Recharla N, Geesala R, Shi XZ. Gut Microbial Metabolite Butyrate and Its Therapeutic Role in Inflammatory Bowel Disease: A Literature Review. Vol. 15, *Nutrients*. Multidisciplinary Digital Publishing Institute (MDPI); 2023.
25. Facchin S, Bertin L, Bonazzi E, Lorenzon G, De Barba C, Barberio B, et al. Short-Chain Fatty Acids and Human Health: From Metabolic Pathways to Current Therapeutic Implications. Vol. 14, *Life*. Multidisciplinary Digital Publishing Institute (MDPI); 2024.
26. Cao Y, Chen J, Xiao J, Hong Y, Xu K, Zhu Y. Butyrate: a bridge between intestinal flora and rheumatoid arthritis. Vol. 15, *Frontiers in Immunology*. Frontiers Media SA; 2024.
27. Hamer HM, Jonkers D, Venema K, Vanhoutvin S, Troost FJ, Brummer RJ. Review article: The role of butyrate on colonic function. Vol. 27, *Alimentary Pharmacology and Therapeutics*. 2008. p. 104–19.
28. Zheng L, Kelly CJ, Battista KD, Schaefer R, Lanis JM, Alexeev EE, et al. Microbial-Derived Butyrate Promotes Epithelial Barrier Function through IL-10 Receptor-Dependent Repression of Claudin-2. *The Journal of Immunology*. 2017;199:2976–84.
29. Salvi PS, Cowles RA. Butyrate and the intestinal epithelium: Modulation of proliferation and inflammation in homeostasis and disease. Vol. 10, *Cells*. MDPI; 2021.
30. Flint HJ, Duncan SH, Scott KP, Louis P. Links between diet, gut microbiota composition and gut metabolism. In: *Proceedings of the Nutrition Society*. Cambridge University Press; 2014.

31. Verhaar BJH, Prodan A, Nieuwdorp M, Muller M. Gut microbiota in hypertension and atherosclerosis: A review. *Nutrients*. 2020;12:1–22.
32. Shen X, Li L, Sun Z, Zang G, Zhang L, Shao C, et al. Gut Microbiota and Atherosclerosis—Focusing on the Plaque Stability. Vol. 8, *Frontiers in Cardiovascular Medicine*. Frontiers Media SA; 2021.
33. Xiao Y, Guo Z, Li Z, Ling H, Song C. Role and mechanism of action of butyrate in atherosclerotic diseases: a review. Vol. 131, *Journal of Applied Microbiology*. John Wiley and Sons Inc; 2021. p. 543–52.
34. Aguilar EC, Leonel AJ, Teixeira LG, Silva AR, Silva JF, Pelaez JMN, et al. Butyrate impairs atherogenesis by reducing plaque inflammation and vulnerability and decreasing NFκB activation. *Nutrition, Metabolism and Cardiovascular Diseases*. 2014;24:606–13.
35. Bartolomaeus H, Balogh A, Yakoub M, Homann S, Markó L, Höges S, et al. Short-Chain Fatty Acid Propionate Protects from Hypertensive Cardiovascular Damage. *Circulation*. 2019;139:1407–21.
36. Canfora EE, Jocken JW, Blaak EE. Short-chain fatty acids in control of body weight and insulin sensitivity. Vol. 11, *Nature Reviews Endocrinology*. Nature Publishing Group; 2015. p. 577–91.
37. Halvorsen B, Wæhre T, Scholz H, Damås JK, Yndestad A, Aukrust P. Role of interleukin-10 in atherogenesis and plaque stabilization. Vol. 2, *Future Cardiology*. 2006. p. 75–83.
38. Sawicka-smiarowska E, Bondarczuk K, Bauer W, Niemira M, Szalkowska A, Raczkowska J, et al. Gut microbiome in chronic coronary syndrome patients. *J Clin Med*. 2021;10.
39. Dou X, Gao N, Yan D, Shan A. Sodium butyrate alleviates mouse colitis by regulating gut microbiota dysbiosis. *Animals*. 2020;10:1–11.
40. Wang R, Yang X, Liu J, Zhong F, Zhang C, Chen Y, et al. Gut microbiota regulates acute myeloid leukaemia via alteration of intestinal barrier function mediated by butyrate. *Nat Commun*. 2022;13.
41. Bihan DG, Rydzak T, Wyss M, Pittman K, McCoy KD, Lewis IA. Method for absolute quantification of short chain fatty acids via reverse phase chromatography mass spectrometry. *PLoS One*. 2022;17.
42. Mohananey D, Masri A, Desai RM, Dalal S, Phelan D, Kanj M, et al. Appropriate Referrals of Angiography Despite High Prevalence of Normal Coronary Arteries or Nonobstructive CAD. Vol. 69, *Journal of the American College of Cardiology*. Elsevier USA; 2017. p. 2672–3.
43. Firdaus I RAYFLAKALO et al. Panduan Praktik Klinis (PPK) dan Clinical Pathway (CP) Penyakit Jantung dan Pembuluh Darah. 1st ed. Vol. 1. Jakarta: PERKI; 2016.
44. Ambrosini AP, Fishman ES, Damluji AA, Nanna MG. Chronic Coronary Disease in Older Adults. Vol. 108, *Medical Clinics of North America*. W.B. Saunders; 2024. p. 581–94.
45. Bhuiyan DrMAS, Roy DrAK, Chowdhury DrUWK, Sharker DrMA, Uddin DrMJ, Saha DrB, et al. Chronic Coronary Syndrome: A Cross-Sectional Study in a Tertiary Care Setting. *Scholars Journal of Applied Medical Sciences*. 2025;13:585–90.
46. Ghani L, Novriani H, Penelitian P, Pengembangan D, Daya S, Kesehatan P, et al. Faktor Risiko Dominan Penyakit Jantung Koroner di Indonesia DOMINANT RISK FACTORS OF CORONARY HEART DISEASE IN INDONESIA.

47. Koskinas KC, Van Craenenbroeck EM, Antoniadou C, Blüher M, Gorter TM, Hanssen H, et al. Obesity and cardiovascular disease: an ESC clinical consensus statement. Vol. 45, *European Heart Journal*. Oxford University Press; 2024. p. 4063–98.
48. Dungan MM, Bracken RC, Wassenaar JW, Fehrenbach DJ, Gonzalez AL, Fuller KK, et al. Abstract 1029: Angiotensin II-induced Hypertension Promotes Innate Immune Memory And Predisposes To Atherosclerosis Progression. *Arterioscler Thromb Vasc Biol* [Internet]. 2024;44:A1029–A1029. Available from: https://doi.org/10.1161/atvb.44.suppl_1.1029
49. Kumar A, Shariff M. Atherosclerotic cardiovascular disease risk score: Are Indians underestimating the risk of cardiovascular disease? Vol. 71, *Indian Heart Journal*. Elsevier B.V.; 2019. p. 364–5.
50. Poznyak A V., Sadykhov NK, Kartuesov AG, Borisov EE, Melnichenko AA, Grechko A V., et al. Hypertension as a risk factor for atherosclerosis: Cardiovascular risk assessment. Vol. 9, *Frontiers in Cardiovascular Medicine*. Frontiers Media S.A.; 2022.
51. Gaggini M, Gorini F, Vassalle C. Lipids in Atherosclerosis: Pathophysiology and the Role of Calculated Lipid Indices in Assessing Cardiovascular Risk in Patients with Hyperlipidemia. Vol. 24, *International Journal of Molecular Sciences*. MDPI; 2023.
52. Fernández-Friera L, Fuster V, López-Melgar B, Oliva B, García-Ruiz JM, Mendiguren J, et al. Normal LDL-Cholesterol Levels Are Associated With Subclinical Atherosclerosis in the Absence of Risk Factors. *J Am Coll Cardiol*. 2017;70:2979–91.
53. Mhaimeed O, Burney ZA, Schott SL, Kohli P, Marvel FA, Martin SS. The importance of LDL-C lowering in atherosclerotic cardiovascular disease prevention: Lower for longer is better. *Am J Prev Cardiol*. 2024;18.
54. Oumer H, Ephrem A, Bacha D, Mohammed S, Getachew H, Haile K. The clinical profile and angiographic characteristics of patients with coronary artery disease at Saint Peter's Specialized Hospital, Addis Ababa, Ethiopia. 2023;6. Available from: <https://ejphn.ephi.gov.et/>
55. Dalile B, Van Oudenhove L, Vervliet B, Verbeke K. The role of short-chain fatty acids in microbiota–gut–brain communication. Vol. 16, *Nature Reviews Gastroenterology and Hepatology*. Nature Publishing Group; 2019. p. 461–78.
56. Stø K, Valeur J, Ueland T, Malmstrøm GH, Bjerkeli V, Trøseid M, et al. Fecal level of butyric acid, a microbiome-derived metabolite, is increased in patients with severe carotid atherosclerosis. *Sci Rep*. 2022;12.
57. Jie Z, Xia H, Zhong SL, Feng Q, Li S, Liang S, et al. The gut microbiome in atherosclerotic cardiovascular disease. *Nat Commun*. 2017;8.
58. Zhu Q, Gao R, Zhang Y, Pan D, Zhu Y, Zhang X, et al. Dysbiosis signatures of gut microbiota in coronary artery disease. *Physiol Genomics* [Internet]. 2018;50:893–903. Available from: <http://drive5.com/uparse/>
59. Magliocca G, Mone P, Di Iorio BR, Heidland A, Marzocco S. Short-Chain Fatty Acids in Chronic Kidney Disease: Focus on Inflammation and Oxidative Stress Regulation. Vol. 23, *International Journal of Molecular Sciences*. MDPI; 2022.
60. Chen L, Mou X, Li J, Li M, Ye C, Gao X, et al. Alterations in gut microbiota and host transcriptome of patients with coronary artery disease. *BMC Microbiol*. 2023;23.